Personen

TOP 5 Publikationen:

1. Bach P, Luderer M, Müller UJ, Jakobs M, Baldermann JC, Voges J, Kiening K, Lux A, Visser-Vandewalle V, DeBraSTRA study group , Bogerts B, Kuhn J, Mann K. Deep brain stimulation of the nucleus accumbens in treatment-resistant alcohol use disorder: a double-blind randomized controlled multi-center trial.Transl Psychiatry. 2023 13(1):49.
2. Gerhardt S, Luderer M, Bumb JM, Sobanski E, Moggi F, Kiefer F, Vollstädt-Klein S. Stop What You're Doing!-An fMRI Study on Comparisons of Neural Subprocesses of Response Inhibition in ADHD and Alcohol Use Disorder.Front Psychiatry. 2021 12:691930.
3. Vollstädt-Klein S, Gerhardt S, Lee A, Strosche A, Sharafi G, Nuriyeva R, Seidt J, Hennig O, Alm B, Hermann D, Sommer WH, Kiefer F, Luderer M, Sobanski E. Interaction between behavioral inhibition and neural alcohol cue-reactivity in ADHD and alcohol use disorder.Psychopharmacology (Berl). 2020 237(6):1691-1707. Epub 2020 Apr 13.
4. Brynte C, Aeschlimann M, Barta C, Begeman AHA, Bäcker A, Crunelle CL, Daigre C, De Fuentes-Merillas L, Demetrovics Z, Dom G, López LG, Icick R, Johnson B, Joostens P, Kapitány-Fövény M, Karsinti E, Kiefer F, Konstenius M, Levin FR, Luderer M, Markus W, Matthys F, Moggi F, Palma-Alvarez RF, Paraskevopoulou M, Ramos-Quiroga JA, Schellekens A, Soravia LM, Therribout N, Thomas A, van de Glind G, van Kernebeek MW, Vollstädt-Klein S, Vorspan F, van den Brink W, Franck J. The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study.BMC Psychiatry. 2022 22(1):625.
5. Reinhardt S, Stoye N, Luderer M, Kiefer F, Schmitt U, Lieb K, Endres K. Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer's disease hallmarks.Sci Rep. 2018 8(1):1329.